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Atopic and non-atopic eczema
Sara Brown, Nick J Reynolds
Atopic eczema is a chronic, relapsing, inflammatory
skin condition associated with epidermal barrier
dysfunction. This article provides a summary of
current knowledge on eczema and its management.
Sources and selection criteria
We used the following sources of information to write
this review:
x PubMed search using the key words “atopic
eczema”, “atopic dermatitis”, “incidence”, “genetics”,
“pathogenesis”, “treatment”, and “management”. We
gave preference to original articles published in the
past three years and recent review articles published in
high impact journals
x Search of the following Cochrane Library data-
bases: Cochrane Database of Systemic Reviews;
Database of Abstracts and Reviews of Effectiveness;
Cochrane Central Register of Controlled Trials
x Personal archive of references.
How do we define atopic eczema?
Atopic eczema and atopic dermatitis are terms that
have been used synonymously (for a clinical definition
see box), but a review committee by the World Allergy
Organisation has published its recommended termi-
nology (see fig 1).1
Eczema is subdivided into atopic and non-atopic
eczema because a proportion of patients exhibit eczema
without atopic features. Children with atopic eczema are
more likely than those with non-atopic eczema to
develop asthma later in life, and their eczemamore often
persists into adulthood. However, atopic and non-atopic
eczema have not been shown to respond differently to
treatment, and patients with non-atopic eczema may
subsequently develop atopic features.
The results of future studies relating clinical
features, pathogenesis, and molecular genetics may
lead to a clearer understanding and more accurate
subclassification of eczema.
Why is eczema important?
Itch as a symptom is often underestimated in terms of
the problems that it can cause. Sleep disturbance and
worries about appearance are often reported, as well as
feelings of guilt and frustration as a consequence of a
child’s eczema.
Although the effects of total sleep deprivation on
human health are well recognised, recent studies have
highlighted that recurrent, partial sleep disturbance
(often occurring in patients with atopic eczema) also
results in considerable neurocognitive impairment.
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Fig 1 Subgroups of dermatitis. Some patients may have a
combination of subgroup types
Summary points
Atopic eczema is an itchy inflammatory skin
condition with associated epidermal barrier
dysfunction
The prevalence of atopic eczema seems to be
rising, but the factors responsible for this rise are
not fully understood
The pathophysiology of eczema involves systemic
as well as cutaneous immune and epidermal
dysfunction
Eczema is a complex trait with significant genetic
and environmental influences
Emollients and topical steroids are the mainstay
of treatment for mild to moderate eczema;
moderate to severe eczema may require the
addition of second line agents such as topical or
systemic calcineurin inhibitors, ultraviolet
phototherapy, or systemic azathioprine
A clearer understanding of the genetic basis and
pathophysiology of eczema is expected to lead to
new improved treatments
A more comprehensive, unedited version of this article is
available on bmj.com
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When taken together, the social, emotional, and
financial effects seem greater on a family looking after
a child with moderate to severe eczema than on a fam-
ily caring for a child with type 1 diabetes.3
Epidemiology
Prevalence and incidence of atopic eczema
The prevalence of atopic eczema varies widely between
populations, with estimates of less than 2% in children
in China and Iran but up to 20% in northern and west-
ern Europe, Australia, and the United States. Many
studies have reported an increasing prevalence, but
some recent research has suggested stable prevalence
and incidence.4 5
Importance of environmental factors
Any recent increase in prevalence cannot be explained
by genetic change, and environmental influences must
therefore play a role in phenotypic expression. Migrant
studies suggest a strong link between atopic eczema and
environmental factors. A higher incidence of atopic
eczema is associated with urban and industrial settings,
higher socioeconomic status, and smaller family size.
These observations have contributed to the so
called “hygiene hypothesis”—that is, infections early in
life give protection against the development of atopic
disease. Some but not all research findings support this
hypothesis.6
Little is known about the role of dietary factors in
the aetiology of eczema. A protective effect of breast
feeding has been postulated, but the evidence is
conflicting. A Cochrane review concluded that there is
inadequate evidence to advise women to avoid specific
foods during pregnancy or breast feeding with the aim
of protecting their children from atopic diseases.7
Pathophysiology—what do we know?
The clinical phenotype of eczema has a multifactorial
aetiology, and the pathophysiology is not fully
understood.
Immune dysfunction
Many inter-related components of the immune system
are known to be dysfunctional in the context of atopic
eczema (table). There is cutaneous hyper-reactivity to
environmental triggers that would be innocuous to
non-atopic individuals, and barrier function is dis-
turbed in the clinically uninvolved skin of patients with
atopic eczema as well as within eczema lesions.
Are allergies important?
It is well established that patients with atopic eczema
may become sensitised to common food and environ-
mental allergens. However, whether these reactions are
responsible for precipitating or maintaining atopic
dermatitis remains controversial. For example, a
placebo controlled double blind trial showed that vari-
ous measures to reduce house dust mites could
improve severe atopic eczema,8 but this finding was not
reproduced in a more recent study with similar design.9
Clinical experience suggests that food allergy is not
commonly an important factor in the relapse of atopic
dermatitis; in the small number of patients in whom
food allergy is important, this is usually obvious to the
patient or their carers.
Non-allergic factors
x Irritants such as detergents disrupt the barrier func-
tion of skin and may precipitate flare-ups of
pre-existing dermatitis.
x Pruritus results in scratching and causes additional
damage to the skin barrier, predisposing to secondary
infection. This perpetuates the so called “itch-scratch
cycle.”
x Staphylococcus aureus is often isolated from eczema-
tous lesions as well as from uninvolved skin, and over-
growth is associated with relapse of atopic eczema.
x Psychological stress may be an additional environ-
mental stimulus, perhaps through neuroimmunoregu-
lation.
Genetic factors in atopic eczema
Twin studies show that genetic factors are important in
the predisposition to atopic eczema, with concordance
rates of about 0.8 and 0.2 in monozygotic and dizygotic
twin pairs respectively.
Eczema and other atopic disorders show clustering
in families, and children whose parents have atopic
eczema show a higher risk of developing eczema than
children of parents with asthma or hay fever. This sug-
gests that additional skin genes may influence the
eczema phenotype.
Many different candidate genes have been studied
because of their theoretical roles in the aetiology of
atopic eczema. These include the high affinity IgE
receptor (FC RI-), the mast cell chymase gene, the
cytokine gene cluster on chromosome 5q31-33, and
the SPINK5 gene (as mutations in this gene cause
Netherton’s syndrome,10 a rare genodermatosis charac-
teristised by an eczematous rash and raised IgE levels).
Definition of atopic dermatitis*
To qualify as having atopic dermatitis, an individual must have:
• An itchy skin condition in the last 12 months
• Plus three or more of the following:
Onset before 2 years of age (not applicable in child under 4 years)
History of flexural involvement
History of generally dry skin
History of other atopic disease (or history in first degree relative if child is
under 4 years)
Visible flexural dermatitis
These diagnostic criteria have been validated in hospital and community settings
and have used in many epidemiological research studies worldwide
*UK refinement of the Hanifin and Rajka Diagnostic Criteria.2
Some features of the innate and acquired immune systems that are thought to play a
pathological role in atopic eczema
Component of
immune system Mechanism/dysfunction
T lymphocytes
Predominance of TH2 over TH1 subtypes in the systemic immune response
Regulatory T cells (Tregs) are also important
Keratinocytes
Keratinocytes produce cytokines and chemokines to induce cutaneous immune
responses
Atopic keratinocytes have a reduced ability to synthesise antimicrobial peptides
Keratinocytes produce ceramides, which are important in skin barrier function
Antigen presenting cells Langerhans cells and inflammatory dendritic epidermal cells (specific to atopic
eczema skin) play a role in T cell activation
Eosinophils and IgE The roles of allergen specific IgE reactions and autoreactivity remain controversial
Immunopathogenesis is discussed in more detail on the bmj.com web extra.
Clinical review
585BMJ VOLUME 332 11 MARCH 2006 bmj.com
Genome-wide screens in families with atopic
eczema from four different populations have detected
several regions showing linkage with atopic eczema.
Interestingly, only two of these regions have shown a
linkage to asthma or other atopic disorders in more
than one study,11 which indicates that separate genes
may be responsible for eczema. Furthermore, the
regions on 1q21, 3q21, 17q25, and 20p linked to atopic
eczema seem to overlap with known psoriasis suscepti-
bility loci,12 although a recent investigation of the
17q25 locus failed to demonstrate variants in the
known PSORS2 psoriasis locus in children with atopic
eczema.13 The colocalisation of eczema and psoriasis
genes supports the concept that specific skin genes
may influence the eczema phenotype via control of
epidermal function.
A recent large scale DNA microarray analysis has
shown that four genes involved with epidermal differen-
tiation (on chromosome 1q21) show different levels of
expression in eczematous skin compared with controls.14
How to treat atopic eczema
The fluctuating course of atopic eczema and a substan-
tial placebo response highlight the need for ran-
domised controlled trials for the evaluation of
treatments or interventions. Clinical practice indicates
that the management of acute weeping eczema is
rather different from chronic lichenified eczema, but
these factors are not always discussed or included in
the entry criteria of clinical trials.
Mild to moderate eczema: emollients and topical
steroids
Mild to moderate eczema is very common and patients
are usually managed in primary care. The mainstay of
treatment remains the appropriate use of emollients and
topical steroids. Good evidence exists to support the effi-
cacy of topical steroids, which need only be applied once
daily. Surprisingly, however, there is limited evidence to
support the beneficial effects of emollients, although
they have been shown to reduce the requirements for
topical steroids by up to 50%.15 Short term bursts of
potent topical steroid are equivalent to prolonged use of
mild steroids,16 and prolonged use of intermittent potent
steroids (two days a week) can reduce the frequency of
flare-ups compared with emollient.17
The importance of a multidisciplinary approach is
increasingly recognised, especially for patient and fam-
ily education, including information about avoidance
of irritants and allergens and about how to use topical
treatments. Patient and carers are often anxious about
the potential side effects of topical steroids, and appro-
priate education is important to avoid overtreatment
or undertreatment.
It is important to recognise complications such as
secondary bacterial infection, eczema herpeticum
(herpes simplex virus infection), and skin atrophy
induced by the overuse of topical steroids. Indications
for referral to secondary care include concern over
diagnosis, a poor response to first line treatment, and
the development of complications.
Moderate to severe eczema: second line treatments
Second line treatments for patients whose eczema has
not responded to adequate topical steroids include
topical calcineurin inhibitors, ultraviolet (UV) photo-
therapy, and systemic agents. Good evidence exists for
the efficacy of these treatments, but longer term studies
to monitor safety are now required, as well as compari-
sons between the treatments.
Topical calcineurin inhibitors
The discovery that systemic ciclosporin is an effective
treatment for atopic eczema led to the development
of topical calcineurin inhibitors, and tacrolimus
and pimecrolimus have been introduced into clinical
practice.
A recent systematic review18 and meta-analysis19
found limited evidence that pimecrolimus is more
effective than placebo in treating mild to moderate
atopic eczema and that tacrolimus is more effective
than placebo and mild topical steroids in treating
moderate to severe atopic eczema. Since then, a
randomised controlled trial involving 487 adult
patients with moderate to severe atopic eczema has
shown that 0.1% tacrolimus was more effective than
moderately potent topical steroids at achieving at least
a 60% improvement at three months (73% and 52%
of patients respectively).20 Formal evidence is
lacking, however, for the efficacy of these agents in
patients who have failed to respond to topical
steroids.
A sensation of skin burning may be troublesome
during the first weeks of treatment; the long term
safety profile of topical calcineurin inhibitors is
currently unknown. Post-marketing reports of tumour
development in patients using topical calcineurin
inhibitors combined with reports of lymphoma in
non-human primates treated with systemic pime-
crolimus have raised concerns. Topical calcineurin
inhibitors are therefore currently recommended as
second line agents. According to their licence, they
should be prescribed by doctors with a special interest
and experience in skin diseases for short term or
intermediate use in patients who have had atopic
eczema for more than two years and are unresponsive
to conventional treatment (www.fda.gov/cder/drug/
advisory/elidel_protopic.htm) (press release No 038,
2004, National Institute for Health and Clinical Excel-
lence (www.nice.org.uk)).
UV phototherapy: UVB v UVA
Patients with atopic eczema often report improvement
after exposure to natural sunlight. A randomised con-
trolled trial involving 73 patients with moderate to
severe atopic eczema found that twice weekly narrow
band (311 nm) UVB for 12 weeks induced a 28%mean
reduction in disease activity compared with a 1.3%
mean reduction from exposure to visible light
(placebo).21 Significant improvement was maintained
at three months. The treatment was well tolerated, but
the potential increased risk of skin cancer needs to be
explained to patients and monitored in the longer
term.
In contrast, UV exposure from conventional
sunbeds (predominantly UVA, 315-400 nm) seemed
relatively ineffective. High dose UVA1 (340-400 nm)
improves acute severe eczema, but specialist irradiation
devices are required. A further comparison of narrow
band UVB versus medium dose UVA1 showed that
narrow band UVB was more effective.22
Clinical review
586 BMJ VOLUME 332 11 MARCH 2006 bmj.com
Systemic immunosuppressants: ciclosporin and azathioprine
Moderate to severe atopic eczema may be only
partially responsive to topical agents and may relapse
after phototherapy; systemic agents may therefore
need to be considered. Moderate to severe disease is
more common in adults than children, and ethical
issues mean that the randomised controlled trials of
systemic agents have principally involved adults.
The efficacy of ciclosporin in the treatment of
moderate to severe atopic eczema is well established.
An open study in adults found that one to two six-week
courses of ciclopsorin resulted in long term remission
of atopic eczema at one year,23 but open trials in
children found that continuous rather than intermit-
tent usage achieved better control.24
Careful monitoring is required with ciclosporin
use. Documented side effects include nephrotoxicity,
immunosuppression, and predisposition to cancer,
particularly cutaneous non-melanoma skin cancer and
lymphoma. Direct evidence with respect to atopic
eczema is currently confined to case reports.
Several open studies found that azathioprine, a
purine analogue, may be effective in moderate to
severe disease, and this has been confirmed by two
recent randomised controlled trials.25 26 The results of a
crossover trial using 2.5 mg/kg azathioprine showed a
25% improvement in disease activity, but 35% of the
participants withdrew owing to side effects. Using a
parallel group design and using doses of azathioprine
according to thiopurinemethyltransferase (TPMT), a
key enzyme in thiopurine metabolism status,Meggitt et
al observed a larger mean improvement in disease
activity (37%) and a lower dropout rate of 15%.
Sustained improvement for at least three months after
stopping azathioprine may also occur.26 In a retrospec-
tive open study, Murphy et al found that azathioprine
resulted in a “good” or “excellent” response in 41/48
(85%) children with atopic eczema.27
Dose dependent nausea is the commonest side
effect of azathioprine, followed by bone marrow and
hepatic toxicity. In the randomised controlled trials, no
participants developed serious laboratory abnormali-
ties, although hypersensitivity to azathioprine occurred
in two patients.26
Measurement of TPMT is now recommended
before azathioprine is started. The aim is (a) to exclude
patients who have absent TPMT activity because they
are at profound risk of developing myelotoxicity28 and
(b) to facilitate lower dosing in patients who have low
TPMT activity.26 Regular haematological monitoring is
still required as polymorphisms in other enzymes may
contribute up to 35% of episodes of neutropenia in
patients receiving azathioprine.29
The longer term risks of azathioprine in atopic
eczema are unknown, but data from patients with
rheumatoid arthritis and inflammatory bowel disease
suggest that any risk of malignancy is small.30
Other systemic agents
Various systemic immunosuppressives, immunomodu-
lators, and antimetabolites have been reported in case
series or uncontrolled trials to be of benefit in patients
with moderate to severe atopic eczema.
Mycophenolate mofetil (MMF) is an immunosup-
pressive drug, and its active metabolite, mycophenolic
acid, selectively inhibits de novo purine synthesis in
lymphocytes through an effect on inosine monophos-
phate dehydrogenase. Two open trials using 2.0 g
MMF daily reported improvement in disease activity
(68% median reduction and 55% mean reduction),31 32
whereas a third study using 2.0-2.5 g daily reported no
clinically relevant effect in five patients.
Adverse effects of MMF relate principally to its
inhibitory effects on the haematopoietic and immune
system—including leucopenia, lymphopenia, and anae-
mia and require appropriate monitoring—but sympto-
matic side effects include gastrointestinal disturbance.
An increased risk of herpetic infections was reported
when mycophenolic acid was originally introduced for
treating psoriasis,33 which may be of concern for
patients with atopic eczema, and indeed one patient
developed herpes retinitis.
Do probiotics help to prevent atopic eczema?
Probiotics are live bacterial cultures of commensal gut
microflora that if taken orally may modulate the
immune system.
Clinical features of eczema
Atopic eczema is characterised by itching and ill defined areas of redness and
scaling typically affecting the limb flexures. The face may also be affected,
particularly in infants and adults, but eczema may affect any part of the skin
surface. In the acute stage, vesiculation, weeping, and crusting may occur.
Lichenification (skin thickening) may predominate in the chronic phase.
Fig 2 Left: Ill defined areas of erythema with multiple excoriations. Right (top): Flexural
eczema showing crusting associated with secondary bacterial infection. Right (bottom):
Erythema, scale, and lichenification on posterior neck
Additional educational resources
British Association of Dermatologists (www.bad.org.uk/healthcare/guidelines/)—
Provides evidence based and up to date information for healthcare professionals
Online manual of the UK Diagnostic Criteria for atopic dermatitis
(www.nottingham.ac.uk/dermatology/eczema/index.html)
National Institute for Health and Clinical Excellence
(www.nice.org.uk/search.aspx?search-mode = simple&ss = eczema)—
Provides national guidance in England and Wales on the treatment of eczema
Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al.
Guidelines for care of atopic dermatitis, developed in accordance with the
American Academy of Dermatology (AAD)/American Academy of
Dermatology Association “Administrative Regulations for Evidence-Based
Clinical Practice Guidelines.” J Am Acad Dermatol 2004;50:391-404.
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A randomised placebo controlled trial found that
when Lactobacillus GG was given prenatally to mothers
for two to four weeks and to their infants (or
breastfeeding mothers) at risk of atopic disease for six
months, the frequency of eczema was reduced from
46% to 23% at two years. The severity of atopic eczema
and IgE reactivity, however, was unchanged.34 A
follow-up study found a persistent beneficial effect of
Lactobacillus GG at four years with respect to frequency
of eczema but not eczema severity. However, the preva-
lence of eczema in the placebo group was relatively
high (46%). In contrast, no evidence exists to indicate
that probiotics improve established atopic eczema.
Conclusion
Eczema is a common and distressing condition. The
aetiology and immunopathogenesis are not fully
understood, and therapeutic options are relatively lim-
ited. Developments in the rapidly advancing fields of
research in eczema epidemiology, pathogenesis, and
genetics will hopefully soon lead to management strat-
egies that are more specifically targeted at pathogenic
mechanisms.
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British Association of Dermatologists (www.bad.org.
uk/public/leaflets)—Information on the diagnosis and treatment of eczema
and other skin conditions
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information leaflets
American Academy of Dermatology’s patient information service
(www.aad.org/public/publications/pamphlets/eczemaatopic dermatitis.htm)
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